Alps Advisors Inc Sage Therapeutics, Inc. Transaction History

Alps Advisors Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $5,159 - $15,085	308 Added 0.7%	44,238 $910,000
Q2 2023 Aug 14, 2023	BUY	$40.65 - $59.54 $186,380 - $272,990	4,585 Added 11.65%	43,930 $2.07 Million
Q1 2023 May 10, 2023	SELL	$37.27 - $46.57 $36,710 - $45,871	-985 Reduced 2.44%	39,345 $1.65 Million
Q4 2022 Feb 14, 2023	BUY	$32.2 - $43.61 $253,864 - $343,821	7,884 Added 24.3%	40,330 $1.54 Million
Q3 2022 Nov 14, 2022	SELL	$32.28 - $43.27 $83,669 - $112,155	-2,592 Reduced 7.4%	32,446 $1.27 Million

Q2 2022 Aug 11, 2022	SELL	$27.52 - $37.99 $705,998 - $974,595	-25,654 Reduced 42.27%	35,038 $1.13 Million
Q1 2022 May 16, 2022	SELL	$30.71 - $45.71 $229,772 - $342,002	-7,482 Reduced 10.97%	60,692 $2.01 Million
Q4 2021 Feb 09, 2022	SELL	$37.06 - $47.11 $144,682 - $183,917	-3,904 Reduced 5.42%	68,174 $2.9 Million
Q3 2021 Nov 15, 2021	SELL	$40.26 - $57.37 $365,399 - $520,690	-9,076 Reduced 11.18%	72,078 $3.19 Million
Q2 2021 Aug 11, 2021	BUY	$54.88 - $79.29 $4.21 Million - $6.08 Million	76,719 Added 1729.85%	81,154 $4.61 Million
Q1 2021 May 07, 2021	BUY	$70.65 - $96.76 $313,332 - $429,130	4,435 New	4,435 $332,000
Q4 2017 Feb 05, 2018	SELL	$60.72 - $167.34 $2.24 Million - $6.17 Million	-36,874 Closed	0 $0
Q3 2017 Nov 03, 2017	BUY	$61.4 - $88.52 $2.26 Million - $3.26 Million	36,874	36,874 $2.3 Million

222

52.7M

207K

191K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $641M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.